The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...
NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to ...
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
NHS England has asked NICE to consider a slow phased rollout of tirzepatide for weight loss in primary care to avoid overwhelming GPs.
In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...
Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...
NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...
Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback